Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
general
Prediction of impending type 1 diabetes through automated dual-label measurement of proinsulin: C-peptide ratio
PLoS ONE, Volume 11, No. 12, Article e0166702, Year 2016
Notification
URL copied to clipboard!
Description
Background: The hyperglycemic clamp test, the gold standard of beta cell function, predicts impending type 1 diabetes in islet autoantibody-positive individuals, but the latter may benefit from less invasive function tests such as the proinsulin:C-peptide ratio (PI:C). The present study aims to optimize precision of PI:C measurements by automating a dual-label trefoil-type timeresolved fluorescence immunoassay (TT-TRFIA), and to compare its diagnostic performance for predicting type 1 diabetes with that of clamp-derived C-peptide release. Methods: Between-day imprecision (n = 20) and split-sample analysis (n = 95) were used to compare TT-TRFIA (AutoDelfia, Perkin-Elmer) with separate methods for proinsulin (in-house TRFIA) and C-peptide (Elecsys, Roche). High-risk multiple autoantibody-positive firstdegree relatives (n = 49; age 5-39) were tested for fasting PI:C, HOMA2-IR and hyperglycemic clamp and followed for 20-57 months (interquartile range). Results: TT-TRFIA values for proinsulin, C-peptide and PI:C correlated significantly (r2 = 0.96-0.99; P<0.001) with results obtained with separate methods. TT-TRFIA achieved better betweenday %CV for PI:C at three different levels (4.5-7.1 vs 6.7-9.5 for separate methods). In high-risk relatives fasting PI:C was significantly and inversely correlated (rs = -0.596; P<0.001) with first-phase C-peptide release during clamp (also with second phase release, only available for age 12-39 years; n = 31), but only after normalization for HOMA2-IR. In ROC- and Cox regression analysis, HOMA2-IR-corrected PI:C predicted 2-year progression to diabetes equally well as clamp-derived C-peptide release. Conclusions The reproducibility of PI:C benefits from the automated simultaneous determination of both hormones. HOMA2-IR-corrected PI:C may serve as a minimally invasive alternative to the more tedious hyperglycemic clamp test. © 2016 Van Dalem et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Authors & Co-Authors
Balti Vounsia, Eric
Belgium, Brussels
Vrije Universiteit Brussel
Keymeulen, Bart
Belgium, Brussels
Vrije Universiteit Brussel
Belgium, Jette
Universitair Ziekenhuis Brussel
Lapauw, Bruno M.
Belgium, Ghent
Universitair Ziekenhuis Gent
De Block, Christophe E.M.
Belgium, Edegem
Universitair Ziekenhuis Antwerpen
Pipeleers, Daniël G.
Belgium, Brussels
Vrije Universiteit Brussel
Weets, Ilse
Belgium, Brussels
Vrije Universiteit Brussel
Belgium, Jette
Universitair Ziekenhuis Brussel
Gorus, Frans K.
Belgium, Brussels
Vrije Universiteit Brussel
Belgium, Jette
Universitair Ziekenhuis Brussel
Verhaeghen, Katrijn
Belgium, Brussels
Vrije Universiteit Brussel
Goubert, Patrick
Belgium, Brussels
Vrije Universiteit Brussel
Statistics
Citations: 14
Authors: 9
Affiliations: 7
Identifiers
Doi:
10.1371/journal.pone.0166702
ISSN:
19326203
Research Areas
Health System And Policy
Noncommunicable Diseases
Study Approach
Quantitative